Related Experiment Videos
Hemolytic uremic syndrome associated with clopidogrel: a case report
1Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass, USA.
Archives of Internal Medicine
|May 16, 2000
Summary
Clopidogrel, an antiplatelet drug, is increasingly used over ticlopidine due to safety concerns. However, a case report suggests clopidogrel may also cause hemolytic uremic syndrome (HUS).
Area of Science:
- Cardiology
- Hematology
- Pharmacology
Background:
- Clopidogrel and ticlopidine are antiplatelet agents prescribed for cerebrovascular and peripheral vascular diseases, and post-coronary stenting to prevent thrombosis.
- Ticlopidine carries risks of severe hematologic adverse effects, including neutropenia and thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (HUS).
- Clopidogrel, a ticlopidine analogue, was developed to have a better safety profile, with no observed bone marrow toxicity in preclinical studies.
Observation:
- Human studies indicated clopidogrel has a low incidence of severe neutropenia and no reported cases of HUS or thrombotic thrombocytopenic purpura.
- Consequently, clopidogrel has become the preferred agent over ticlopidine for patients undergoing coronary artery stenting.
Findings:
- This report details a case of hemolytic uremic syndrome (HUS) associated with clopidogrel use.
- This finding challenges the previously assumed safety of clopidogrel regarding HUS.
Implications:
- The observation suggests clopidogrel may be a potential causative agent for HUS.
- This case necessitates further investigation into the safety profile of clopidogrel, particularly concerning HUS.
- Clinicians should remain vigilant for HUS in patients treated with clopidogrel.